Weight Loss

Novo Nordisk announced that monlunabant, a novel small molecule oral cannabinoid receptor 1 inverse agonist, was associated with weight loss in a phase 2a study of people with obesity and metabolic syndrome.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

Intermittent and continuous energy restriction diets both improved cardiometabolic measures and reduced symptoms of depression and disordered eating among adolescents with obesity, according to findings published in JAMA Pediatrics.

A dual GLP-1/GLP-2 receptor agonist did not confer greater body weight reductions for adults with obesity and without diabetes at 12 weeks compared with placebo, according to data from a phase 2a proof-of-concept study.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting.

A novel oral GLP-1 receptor agonist was well-tolerated and linked with weight loss compared with placebo in healthy adults with overweight or obesity, according to top-line results of a phase 1 study.

The Healio news team won an APEX Grand Award for its Treating Obesity resource center, a collection of the latest news and perspectives on medications for obesity.

A low-fat vegan diet significantly reduced harmful inflammatory dietary compounds compared with a Mediterranean diet, according to findings from a randomized study.